Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

• ClinicalTrials.gov Identifier: NCT04717531
• Recruitment Status: Recruiting
• First Posted: January 22, 2021
• Last Update Posted: June 4, 2021
• Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Information provided by (Responsible Party): The First Affiliated Hospital with Nanjing Medical University

Study Description

Brief Summary:

The study assesses the efficacy of neoadjuvant treatment with pyrotinib and trastuzumab with chemotherapy, mainly pathological complete response (pCR) rates in the breast and axilla.

And also assesses side effects, event-free survival (EFS), disease-free survival (DFS), distant disease-free survival (DDFS), and objective response rates (ORR).

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: Pyrotinib; Drug: Trastuzumab; Drug: Pertuzumab; Drug: Docetaxel; Drug: Epirubicin; Drug: Cyclophosphamide	Phase 2

Detailed Description:

Investigational Medical Products (IMPs) will be pyrotinib (B), trastuzumab (H), pertuzumab (P), docetaxel (T), epirubicin (E), and cyclophosphamide (C).

Magnetic resonance imaging (MRI) will be performed at baseline and 2 cycles after neoadjuvant therapy with trastuzumab, pertuzumab, and docetaxel (THP*2). Non-objective response patients will be randomly assigned (2:1) to receive 2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib and epirubicin plus cyclophosphamide (THB*2-ECB[epirubicine, cyclophosphamide, and pyrotinib]*4, cohort A), or 2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin plus cyclophosphamide (THP*2-EC*4, cohort B).

During the neoadjuvant therapy, the side effects and all the events were recorded and analyzed. After surgery, the efficacy of pCR rate and ORR were analyzed. And long time follow-up will also be performed to analyze EFS, DFS, DDFS, and ORR.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Pyrotinib as Neoadjuvant Agent for Non-objective Response Patients of HER2-positive Early Breast Cancer Treated by Trastuzumab, Pertuzumab, and Chemotherapy (PYHOPE-BC-104): a Randomized, Controlled, Phase Ⅱ Trial
• Actual Study Start Date: June 3, 2021
• Estimated Primary Completion Date: June 1, 2023
• Estimated Study Completion Date: May 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort A; 2 cycles of pyrotinib and trastuzumab with docetaxel followed by 4 cycles of pyrotinib, epirubicin, and cyclophosphamide (THB*2-ECB*4). The cycles repeated every 21 days. Pyrotinib: 400mg, qd, po, day 1-21; Trastuzumab: 6 mg/kg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90 mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1.	Drug: Pyrotinib; 400mg, qd, po, day 1-21; Other Name: B; Drug: Trastuzumab; 6 mg/kg, day 1; Other Name: H; Drug: Docetaxel; 100 mg/m2, day 1; Other Name: T; Drug: Epirubicin; 90mg/m2, day 1; Other Name: E; Drug: Cyclophosphamide; 600 mg/m2, day 1; Other Name: C
Active Comparator: Cohort B; 2 cycles of trastuzumab and pertuzumab with docetaxel followed by 4 cycles of epirubicin and cyclophosphamide (THP*2-EC*4). The cycles repeated every 21 days. Trastuzumab: 6 mg/kg, day 1; Pertuzumab: 420 mg, day 1; Docetaxel: 100 mg/m2, day 1; Epirubicin: 90mg/m2, day 1; Cyclophosphamide: 600 mg/m2, day 1.	Drug: Trastuzumab; 6 mg/kg, day 1; Other Name: H; Drug: Pertuzumab; 420 mg, day 1; Other Name: P; Drug: Docetaxel; 100 mg/m2, day 1; Other Name: T; Drug: Epirubicin; 90mg/m2, day 1; Other Name: E; Drug: Cyclophosphamide; 600 mg/m2, day 1; Other Name: C

Outcome Measures

Primary Outcome Measures :

1. Pathological complete response (pCR) rate [ Time Frame: up to 30 weeks ]
   Number of patients with pCR (no invasive breast cancer in the breast and axilla)

Secondary Outcome Measures :

1. Number of patients with grade >3 adverse events as a measure of safety and tolerability [ Time Frame: up to 30 weeks ]
   To describe the safety of the various regimens toxicity is compared between the two arms.
2. Objective response rate (ORR) [ Time Frame: up to 30 weeks ]
   ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
3. Disease-free Survival (DFS) [ Time Frame: Following surgery, every 12 months until Year 10 ]
   DFS was defined as the time from surgery to the first date of breast cancer relapse, second primary tumor (including contralateral breast cancer), or death without documented prior relapse. Data will be reported when they are mature and available, likely when a median of 3 years follow up has been reached.
4. Event Free Survival (EFS) [ Time Frame: From date of randomization until follow-up to 10 years ]
   EFS will be defined as the time from random assignment to documentation of the first of the following events: discontinuation of study therapy due to protocol-defined progression prior to surgery; local, regional, or distant recurrence of breast cancer following curative surgery; a new breast cancer; another new onset malignancy; or death as a result of any cause.
5. Distant-disease- free survival (DDFS) [ Time Frame: From date of randomization until follow-up to 10 years ]
   DDFS is defined as the time period from randomization to the first event.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Female patients between 18-70 years old. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 3. Histologically confirmed HER2 (human epidermal growth factor receptor-2)-positive invasive breast cancer.

4. Non-objective response after 2 cycles of THP as neoadjuvant treatment. 5. Known hormone receptor status. 6. Patient has adequate bone marrow, liver, and renal function:

1. Hematological: White blood cell (WBC) count > 3.5 x 109/L, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 90 x109/L, and hemoglobin ≥ 90 g/dL.
2. Hepatic function: total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (except for Gilbert's syndrome); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times ULN.
3. Renal function: serum creatinine and BUN ≤ 1.5 x ULN, or creatinine clearance ≥ 50 ml/min/1.73 m2 for patients with creatinine levels above institutional normal.

8. LVEF ≥50% measured by echocardiography. 9. Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed).

10. Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization (For women of childbearing potential).

11. Signed informed consent form (ICF).

Exclusion Criteria:

1. Metastatic breast cancer;
2. Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix.
3. Patients with a prior malignancy diagnosed more than 10 years prior to randomization may enter the study. Patients must have been curatively treated with surgery alone. Radiation therapy or systemic therapy (chemotherapy or endocrine) are NOT permitted. Prior diagnoses of breast cancer or melanoma are excluded.
4. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;
5. Major surgical procedure or significant traumatic injury within 14 days prior to randomization or anticipation of the need for major surgery within the course of the study treatment.
6. Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (≥180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen;
7. Known hypersensitivity reaction to one of the investigational compounds or incorporated substances.
8. Pregnant or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment.
9. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety.

Contacts and Locations

Contacts

Contact: Jue Wang, MD; 00862568308172; wangjue200011@njmu.edu.cn

Locations

China, Jiangsu

the First Affiliated Hospital of Nanjing Medical University; Recruiting

Nanjing, Jiangsu, China

Contact: Jue Wang, MD 00862568308172 wangjue200011@njmu.edu.cn

Sponsors and Collaborators

The First Affiliated Hospital with Nanjing Medical University

Investigators

• Principal Investigator: Xiaoming Zha, MD; The First Affiliated Hospital with Nanjing Medical University

More Information

• Responsible Party: The First Affiliated Hospital with Nanjing Medical University
• ClinicalTrials.gov Identifier: NCT04717531
• Other Study ID Numbers: PYHOPE-BC-104
• First Posted: January 22, 2021
• Last Update Posted: June 4, 2021
• Last Verified: June 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by The First Affiliated Hospital with Nanjing Medical University:

neoadjuvant; pyrotinib; HER2-positive

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Cyclophosphamide; Docetaxel; Trastuzumab; Epirubicin; Pertuzumab; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Myeloablative Agonists; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Immunological; Antibiotics, Antineoplastic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Enzyme Inhibitors